NASDAQ: TTRXTurn Therapeutics Inc Stock
$9.03-0.55 (-5.74%)
Updated Jul 16, 2026
TTRX Price
$9.03
Fair Value Price
$0.36
Market Cap
$268.99M
52 Week Low
$2.57
52 Week High
$26.50
P/E
-66.89x
P/B
43.97x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$3.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.05
Operating Cash Flow
N/A
Beta
1.4
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TTRX Overview
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TTRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TTRX
Ranked#166 of 467
Ranked#166 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $242.18 | A | |
| $11.13 | A | |
| $15.94 | A |
Be the first to know about important TTRX news, forecast changes, insider trades & much more!
TTRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TTRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TTRX ($9.03) is overvalued by 2,384.25% relative to our estimate of its Fair Value price of $0.36 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TTRX ($9.03) is not significantly undervalued (2,384.25%) relative to our estimate of its Fair Value price of $0.36 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TTRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TTRX due diligence checks available for Premium users.
Valuation
TTRX fair value
Fair Value of TTRX stock based on Discounted Cash Flow (DCF)
Price
$9.03
Fair Value
$0.36
Overvalued by
2,384.25%
TTRX ($9.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TTRX ($9.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TTRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TTRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-66.89x
Industry
21.71x
Market
11.26x
TTRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
43.97x
Industry
5.42x
TTRX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TTRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$971.0k
Profit Margin
0%
Assets to liabilities
Assets
$18.6M
Liabilities
$12.5M
Debt to equity
2.05
TTRX's short-term assets ($11.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TTRX's short-term assets ($11.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TTRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$12.2k
Financing
$7.8M
TTRX vs Biotech Stocks
Turn Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.